(Sharecast News) - Drugmaker GSK revealed on Monday that a new drug application for its linerixibat asset had been accepted for review by the US Food and Drug Administration for use in cholestatic pruritus patients with primary biliary cholangitis.
GSK said its application for linerixibat, an investigational targeted inhibitor of the...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE